BiotechTube

AOC 1001 (del-desiran) + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

DM1

Conditions

DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy

Trial Timeline

May 30, 2024 → Sep 1, 2026

NCT ID
NCT06411288

About AOC 1001 (del-desiran) + Placebo

AOC 1001 (del-desiran) + Placebo is a phase 3 stage product being developed by Avidity Biosciences for DM1. The current trial status is active. This product is registered under clinical trial identifier NCT06411288. Target conditions include DM1, Myotonic Dystrophy, Myotonic Dystrophy 1.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06411288Phase 3Active

Competing Products

6 competing products in DM1

See all competitors
ProductCompanyStageHype Score
VX-670Vertex PharmaceuticalsPhase 2
51
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
40
Placebo + AOC 1001Avidity BiosciencesPhase 2
49
AOC 1001 + PlaceboAvidity BiosciencesPhase 1/2
38
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
72
DYNE-101 + PlaceboDyne TherapeuticsPhase 1/2
36

Other Products from Avidity Biosciences

Del-desiran (AOC 1001)Phase 3
74
AOC-1020 + PlaceboPhase 3
74
Placebo + AOC 1001Phase 2
49
AOC 1020Phase 2
49
AOC 1044Phase 2
49